• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23378 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2023     Canary Health Service [Cost-effectiveness of childhood vaccination against invasive meningococcal disease due to ACWY serogroups]
2023     Canary Health Service [Determination by chemiluminescence of autoantibodies to domain 1 of beta 2 glycoprotein I in patients with antiphospholipid syndrome]
2023     Canary Health Service [Neuropsychological rehabilitation in people with paediatric cancer]
2023     Canary Health Service [Cost-effectiveness of systematic vaccination against invasive meningococcal disease due to serogroup B in childhood]
2023     Canary Health Service [Melanoma detection without biopsy using a non-invasive adhesive patch]
2023     Canary Health Service [Effectiveness, safety and cost-effectiveness of real time continuous glucose monitoring systems, open-loop systems and hybrid closed-loop systems (artificial pancreas) for patients with diabetes]
2023     Canary Health Service [Clinical effectiveness and cost-effectiveness of the extension of colorectal cancer screening up to 74 years of age in general population]
2023     Canary Health Service [Intraoperative radiotherapy in resectable brain tumors and metastases]
2023     Canary Health Service [Genicular artery embolization for the treatment of knee osteoarthritis]
2023     Canary Health Service [Targeted muscle reinnervation in individuals with amputated limbs]
2023     Canary Health Service [Transcranial direct current stimulation device for the treatment of drug-resistant epilepsy]
2023     Canary Health Service [Software to support decisions for the administration of medicines in neonatal and paediatric intensive care units]
2023     National Institute for Health and Care Excellence (NICE) MRI-based technologies for assessing non-alcoholic fatty liver disease. NICE diagnostics guidance 50
2023     National Institute for Health and Care Excellence (NICE) MRI fusion biopsy systems for diagnosing prostate cancer. NICE diagnostics guidance 53
2023     National Institute for Health and Care Excellence (NICE) Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers. NICE diagnostics guidance 52
2023     National Institute for Health and Care Excellence (NICE) Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2023     National Institute for Health and Care Excellence (NICE) FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. NICE diagnostics guidance 48
2023     National Institute for Health and Care Excellence (NICE) AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023     National Institute for Health and Care Excellence (NICE) Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023     National Institute for Health and Care Excellence (NICE) Devices for remote monitoring of Parkinson's disease. NICE diagnostics guidance 51
2023     National Institute for Health and Care Excellence (NICE) AposHealth for knee osteoarthritis. NICE medical technologies guidance 76
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Nivolumab plus ipilimumab in pleural mesothelioma]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [FONAKIDs® multimodal approach in congenital or acquired apraxia of speech]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Use of biomaterials in tympanoplasty for tympanic membrane repair]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation for dystonia refractory to medical treatment]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multiplex PCR for moderate to severe acute lower respiratory tract infections]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Medial pivot prosthesis in primary total knee arthroplasty]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [CROS and BICROS hearing aids in unilateral and asymmetric bilateral hearing loss]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Cannabidiol in epilepsy. National versus international products comparison]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Levonorgestrel-releasing intrauterine device as contraceptive method in women of childbearing age]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency ablation of parathyroid glands]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in triple-negative breast cancer]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Edaravone in amyotrophic lateral sclerosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multigene panel testing for tumors of known origin]
2023     Penn Medicine Center for Evidence-based Practice (CEP) Mortality review 2023 update
2023     HTA South [Focused ultrasound treatment for tremor]
2023     National Institute for Health and Care Excellence (NICE) Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. NICE interventional procedures guidance 747
2023     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical stimulation of the trigeminal nerve for ADHD. NICE interventional procedures guidance 748
2023     National Institute for Health and Care Excellence (NICE) Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. NICE interventional procedures guidance 749
2023     National Institute for Health and Care Excellence (NICE) Trabeculectomy with a biodegradable collagen matrix implant for glaucoma. NICE interventional procedures guidance 750
2023     National Institute for Health and Care Excellence (NICE) Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. NICE interventional procedures guidance 752
2023     National Institute for Health and Care Excellence (NICE) Transvenous obliteration for gastric varices. NICE interventional procedures guidance 751
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transluminal renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 754
2023     National Institute for Health and Care Excellence (NICE) Endoluminal gastroplication for gastro-oesophageal reflux disease. NICE interventional procedures guidance 753
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation for palliation of painful spinal metastases. NICE interventional procedures guidance 758
2023     National Institute for Health and Care Excellence (NICE) Maximal cytoreductive surgery for advanced ovarian cancer. NICE interventional procedures guidance 757
2023     National Institute for Health and Care Excellence (NICE) Focal therapy using high-intensity focused ultrasound for localised prostate cancer. NICE interventional procedures guidance 756
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thoracic duct embolisation for persistent chyle leak. NICE interventional procedures guidance 755
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. NICE interventional procedures guidance 759
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided biliary drainage for biliary obstruction. NICE interventional procedures guidance 761
2023     National Institute for Health and Care Excellence (NICE) Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea. NICE interventional procedures guidance 760
2023     National Institute for Health and Care Excellence (NICE) Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. NICE interventional procedures guidance 762
2023     National Institute for Health and Care Excellence (NICE) Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer. NICE interventional procedures guidance 763
2023     National Institute for Health and Care Excellence (NICE) Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. NICE interventional procedures guidance 765
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. NICE interventional procedures guidance 764
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2023     National Institute for Health and Care Excellence (NICE) Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 766
2023     National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating prostate cancer. NICE interventional procedures guidance 768
2023     National Institute for Health and Care Excellence (NICE) Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease. NICE interventional procedures guidance 769
2023     National Institute for Health and Care Excellence (NICE) Cryotherapy for chronic rhinitis. NICE interventional procedures guidance 771
2023     National Institute for Health and Care Excellence (NICE) Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2023     National Institute for Health and Care Excellence (NICE) Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. NICE interventional procedures guidance 772
2023     National Institute for Health and Care Excellence (NICE) Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. NICE interventional procedures guidance 773
2023     National Institute for Health and Care Excellence (NICE) Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
2023     National Institute for Health and Care Excellence (NICE) Extracorporeal carbon dioxide removal for acute respiratory failure. NICE interventional procedures guidance 776
2023     National Institute for Health and Care Excellence (NICE) Biodegradable subacromial spacer insertion for rotator cuff tears. NICE interventional procedures guidance 775
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. NICE interventional procedures guidance 777
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. NICE interventional procedures guidance 778
2023     National Institute for Health and Care Excellence (NICE) Middle meningeal artery embolisation for chronic subdural haematomas. NICE interventional procedures guidance 779
2023     The Danish Health Technology Council (DHTC) [Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for risdiplam acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A21-131]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burnout: Can yoga help cope?]
2023     Haute Autorite de sante (HAS) [2023 update: clinical utility of genomic signatures in early-stage HR-positive/HER2-negative breast cancer]
2023     Haute Autorite de sante (HAS) [Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations]
2023     Haute Autorite de sante (HAS) [Assessment of the exhaled nitric oxide measurement for asthma management]
2023     The Danish Health Technology Council (DHTC) [Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2023     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness and safety of newborn screening for spinal muscular atrophy. Systematic review]
2023     The Danish Health Technology Council (DHTC) [Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [Low-level light therapy for primary dysmenorrhea]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Contraception: comparison of hormonal coils and copper coils]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023     National Institute for Health and Care Excellence (NICE) Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023     National Institute for Health and Care Excellence (NICE) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of bimekizumab (Bimzelx)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of gefapixant (Lyfnua)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of clazosentan (Pivlaz)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) (Cost-effectiveness evaluation of Valbenazine (Dysval) for tardive dyskinesia)
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Efgartigimod Alfa (Vyvgart)]
2023     HTA Region Stockholm [Effects of nonsteroidal anti-inflammatory drugs (NSAID) on risk of exacerbation of disease in patients with inflammatory bowel disease (IBD)]
2023     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936